Eculizumab in the treatment of membranoproliferative glomerulonephritis
AS Bomback - Nephron Clinical Practice, 2015 - karger.com
A major shift in our understanding of the membranoproliferative glomerulonephritis (MPGN)
lesion is the focus on which components of the complement pathway are involved in …
lesion is the focus on which components of the complement pathway are involved in …
Anti-complement therapy for glomerular diseases
AS Bomback - Advances in Chronic Kidney Disease, 2014 - Elsevier
A major shift in our understanding of glomerular diseases is the focus on which components
of the complement pathway are involved in mediating kidney injury. For example, the …
of the complement pathway are involved in mediating kidney injury. For example, the …
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment
Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury that may
be primary or secondary to infections, autoimmune diseases and haematological disorders …
be primary or secondary to infections, autoimmune diseases and haematological disorders …
Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment
K Kaartinen, L Martola, A Räisänen-Sokolowski… - Clinical …, 2018 - Elsevier
There is a great lack of efficient treatments for membranoproliferative glomerulonephritis
(MPGN) and recently emerged complement therapies have been proposed to be useful. We …
(MPGN) and recently emerged complement therapies have been proposed to be useful. We …
[HTML][HTML] Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy
T Kersnik Levart, D Ferluga, A Vizjak, J Mraz… - Diagnostic …, 2016 - Springer
Background Understanding the role of alternative complement pathway dysregulation in
membranoproliferative glomerulonephritis (MPGN) has led to a dramatic shift in its …
membranoproliferative glomerulonephritis (MPGN) has led to a dramatic shift in its …
Eculizumab in a patient with dense-deposit disease
Eculizumab in a Patient with Dense-Deposit Disease | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
[HTML][HTML] Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion
Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular
injury that is easily recognized by light microscopy. With additional studies, MPGN …
injury that is easily recognized by light microscopy. With additional studies, MPGN …
Eculizumab for the treatment of dense-deposit disease
M Vivarelli, A Pasini, F Emma - New England Journal of Medicine, 2012 - Mass Medical Soc
Eculizumab for the Treatment of Dense-Deposit Disease | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Eculizumab and refractory membranoproliferative glomerulonephritis
S Radhakrishnan, A Lunn, M Kirschfink… - … England Journal of …, 2012 - Mass Medical Soc
Eculizumab and Refractory Membranoproliferative Glomerulonephritis | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
Treatment of C3 glomerulopathy with complement blockers
M Vivarelli, F Emma - Seminars in thrombosis and hemostasis, 2014 - thieme-connect.com
C3 glomerulopathy (C3G) is a newly defined clinical entity comprising glomerular lesions
with predominant C3 staining. Under this definition are now included membranoproliferative …
with predominant C3 staining. Under this definition are now included membranoproliferative …